Orexigen Therapeutics Inc. signed a North American partnership for its experimental obesity drug Contrave with Takeda Pharmaceutical Co. for $50 million and the potential for later payments that could exceed $1 billion.

Orexigen Signs Obesity-Drug Pact With Takeda – WSJ.com